The FDA issued an emergency use authorization (EUA) for pemivibart (Pemgarda) as COVID-19 pre-exposure prophylaxis in immunocompromised individuals who are unlikely to mount a sufficient immune ...

New protection against COVID-19 is now available for a group of people who need it the most – those who are moderately or severely immunocompromised. The U.S. Food and Drug Administration has ...

On the same day North Carolina hospitals reported a record number of COVID-19 patients in intensive care units across the state, Gov. Roy Cooper signaled he will take action expanding access to a ...

On March 22, the U.S. Food and Drug Administration, or FDA, issued an emergency use authorization for Pemgarda — a new drug that prevents COVID-19 infection — for certain adults and adolescents, ...

Sept 16 (Reuters) - Eli Lilly and Co (LLY.N), opens new tab on Wednesday said a single infusion of its experimental antibody treatment reduced the need for hospitalization and emergency room visits ...

The dominance of the Delta strain of COVID-19 combined with Alabama’s low vaccination rate has led experts to turn to monoclonal antibody infusion, a treatment in which infected individuals are ...

While doctors have stressed the importance of COVID-19 vaccinations, there are also coronavirus treatments helping sick patients stay out of the hospital. Monoclonal antibody therapy is gaining ...

The race is on for new treatments that stand up to omicron's explosive spread. With omicron's explosive spread threatening to outpace current COVID-19 treatments, the race is on to find new options ...

UnitedHealth Group temporarily opened an infusion center in its headquarters of Minnetonka, Minn., to provide eligible COVID-19 patients access to antibody treatments, according to the Star Tribune.

Data supporting antibodies is limited compared to that for authorized vaccines. Despite more than 187 million Americans being fully vaccinated against COVID-19 and data and attestations from ...

"We are clearly in a data-free zone right here," an infectious-disease physician told Business Insider.

(Reuters) -Britain's GSK and partner Vir said on Friday their antibody-based COVID-19 drug was shown in a trial to work as well when given as a shot in the arm awhen administered via the standard ...